Did you know?

DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases ...See the latest Durect Corp stock price (DRRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.ASRT's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.08 -- higher than only 2.12% of US-listed equities with positive expected earnings growth. The price/operating cash flow metric for ASSERTIO HOLDINGS INC is higher than just 4.73% of stocks in our set with a positive cash flow.

Past Earnings Growth Analysis. Earnings Trend: DRRX is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year. Accelerating Growth: Unable to compare DRRX's earnings growth over the past year to its 5-year average as it is currently unprofitable. Earnings vs Industry: DRRX is unprofitable, making it difficult ...DRRX Stock 12 Months Forecast. $8.50. (1187.88% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Durect in the last 3 months. The average price target is $8.50 with a high forecast of $8.50 and a low forecast of $8.50. The average price target represents a 1187.88% change from the last price of $0.66.Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update. Durect Earnings Preview. Track Durect Corp (DRRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.Nov 14, 2023 · Future criteria checks 2/6. DURECT is forecast to grow earnings and revenue by 16.9% and 47.9% per annum respectively while EPS is expected to grow by 19.9% per annum. Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Drrx stock forecast. Possible cause: Not clear drrx stock forecast.

Get the latest Oncology Pharma Inc (ONPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.DRRX's stock price has decreased by -84.09% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 2 stock analysts, the average 12-month stock price forecast for DURECT stock is $36.5, which predicts an increase of 5,499.88%.

DRRX Stock Price Forecast. The average stock forecast for DURECT Corp (DRRX) in the next 12 months is 30.40 USD. This price target corresponds to an upside of 10.83%. The range of stock forecasts for DRRX is 12.12 - 43.05 USD. …DRRX stock forecast Our latest prediction for Durect Corp's stock price was made on the May 26, 2020 when the stock price was at 2.66$. In the short term (2weeks), DRRX's stock price should outperform the market by 4.58%. During that period the price should oscillate between -11.17% and +17.56%.

fintech startups san francisco Elys delivers a true state-of-the-art betting platform, capable of processing any type of digital game content. From integrated sports and virtual betting solutions to any third-party content including online casino & slot games, poker, bingo, lottery plus all types of interactive games, we have decades of experience offering it all.. The difference is the Elys’ … what is the value of 1964 nickelbest custodian for self directed ira May 26, 2020 · DRRX stock forecast Our latest prediction for Durect Corp's stock price was made on the May 26, 2020 when the stock price was at 2.66$. In the short term (2weeks), DRRX's stock price should outperform the market by 4.58%. During that period the price should oscillate between -11.17% and +17.56%. Complete Durect Corp. stock information by Barron's. View real-time DRRX stock price and news, along with industry-best analysis. learn crypto trading GEVO Stock 12 Months Forecast. $6.47. (528.16% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Gevo in the last 3 months. The average price target is $6.47 with a high forecast of $14.00 and a low forecast of $2.00. The average price target represents a 528.16% change from the last price of $1.03. nasdaq returns by yearnasdaq amcxkennedy dollar coin worth Shares of Durect (DRRX) have gained 12.6% over the past four weeks to close the last trading session at $5.18, but there could still be a solid upside left in the stock if short-term price targets ...Biotech Stock Screener. The top biotech stocks list is updated daily after market close. To find low price biotech stocks, go to biotech stocks under $5. 12/1/2023. To get intraday penny stocks update (every 5-10 minutes), please signup for a free account. Symbol. chartergpt Durect (NASDAQ: DRRX) stock is falling hard on Wednesday after the late-stage biopharmaceutical company released results from a Phase 2b clinical trial. This clinical trial covered the efficiency ...Mar 24, 2023 · DRRX stock has massive potential and is up 32% so far this year. Analysts have a price target of $34.50, which would be a lofty 650% bump. DRRX stock has a “B” rating in the Portfolio Grader. premarket movers benzingamedical insurance companies in wvstock portfolio app Get the latest TG Therapeutics Inc common stock (TGTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.